Barbara L. Nye MD is a Board-Certified Neurologist, UCNS Board Certified Headache subspecialist. She is the Director of the Headache Fellowship at Atrium Health – Wake Forest Baptist and Associate Professor of Neurology at Wake Forest School of Medicine. She is honored to serve on the board of the Alliance for Headache Disorders Advocacy
She graduated from the University of South Florida College of Medicine, where she discovered a passion for neurology and then headache medicine. She completed both her residency and sub-specialty training at Dartmouth Hitchcock Medical Center.
She spent 6 years from 2015 to 2021 on faculty at Darthmouth, as an Assistant Professor of neurology, Co-Director of the Headache Center, and Director of the Headache Fellowship. During my tenure there I grew the headache fellowship from one fellow to two fellows per year, I developed a well-rounded curriculum to included inpatient and outpatient headache management, advocacy, and research opportunities for the fellows. She was also a board member of the Headache Cooperative of New England.
She moved to Winston-Salem, NC in Jan 2022 and joined the faculty at Atrium Health – Wake Forest Baptist in the Comprehensive Headache program as the Headache Fellowship Director. I continue to work with patients and provided education to all levels of learners. I participate in clinical education of medical students, residents, and fellows.
She is actively involved in research being the principal investigator on several clinical research studies and involved in quality improvement projects within the clinic/hospital. She continues to enjoy speaking to and teaching patients and providers about headache management and strive to decrease the sigma that my patients face daily.
She has been passionately activating for patients participating in Miles for Migraine run and education events, Headache on the Hill since 2019. When the CGRP medications came to market she took time to meet with the New Hampshire Medicaid medication review board to help ensure that patients would get equal access to novel therapeutics regardless of coverage types.
